DNLI stock news today

Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42

Morgan Stanley stayed positive on Denali Therapeutics and raised its price target to $42. The Overweight rating means the firm still expects the stock to outperform.

Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24

Wedbush reiterated an Outperform rating on Denali Therapeutics and raised its price target to $24. The change reflects the firm's updated view on the stock.

Wedbush lifts Denali Therapeutics target to $24 from $23

An analyst at Wedbush raised the firm's valuation level for Denali Therapeutics by one dollar, moving it to $24. The update concerns the biotech company's stock outlook.

BTIG keeps Buy rating on Denali Therapeutics with $39 target

BTIG repeated its Buy call on Denali Therapeutics and left its $39 price target unchanged. The note restates the firm's existing view on the biotech stock.

Denali Therapeutics Posts Q3 2026 Financials

The biotech company released its quarterly financial figures for the three months ended in 2026. The filing covers its latest period results.

Denali Therapeutics holds Q3 2026 earnings call

Denali Therapeutics discussed its third-quarter 2026 results during an earnings call. The transcript covers the company's quarterly performance.

Denali Therapeutics guides Q4 sales to $30M-$32M, above $22.659M estimate

Denali Therapeutics said it expects fourth-quarter sales of $30 million to $32 million. That range is higher than the $22.659 million estimate.

Denali says zafinofusp alfa Phase 1/2 trial in Sanfilippo syndrome finished primary endpoint treatment period

Denali reported that the primary endpoint treatment period of its Phase 1/2 study of zafinofusp alfa in Sanfilippo syndrome is complete. Data from the trial are expected in the first quarter of 2027.

Denali Therapeutics posts $0.37 per-share profit, revenue of $17.778M for third quarter

The biotech company's quarterly profit and revenue both came in above analyst expectations. It earned $0.37 a share on $17.778 million in sales.

Denali Therapeutics earns 2026 Prix Galien USA honor for AVLAYAH

Denali Therapeutics has been recognized with a 2026 Prix Galien USA accolade tied to AVLAYAH. The prize highlights the company's work on that product.

Wedbush trims its valuation view on Denali Therapeutics, now $23

Wedbush reduced the level it assigns to Denali Therapeutics shares, moving from $27 down to $23. The adjustment is the firm's revised assessment of the stock.

Denali Therapeutics holds Q2 2026 earnings call

Denali Therapeutics discussed its second-quarter 2026 financial results during its earnings call. The transcript covers the company's quarterly performance.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

B. Riley Securities keeps Buy rating on Denali Therapeutics, lifts target to $35

B. Riley Securities reiterated its Buy rating on Denali Therapeutics and raised its price target to $35. The update reflects the firm's latest view on the stock.

What is the latest news on DNLI?

Nov 4, 2026: Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42 (Benzinga) · Nov 4, 2026: Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24 (Benzinga) · Nov 4, 2026: Wedbush lifts Denali Therapeutics target to $24 from $23 (Fiscal.ai)

What has DNLI filed with the SEC recently?

Sep 9, 2026: Denali Therapeutics Inc. filed an insider trading report (Form 4)